Anixa Biosciences
ANIX
Anixa Biosciences (ANIX) news
Recent news
Anixa Biosciences - No dose-limiting toxicities observed to date in CAR-T trial
AInvest Wire · Oct 5, 2026Anixa Biosciences - Multiple patients in trial have survived more than one year, including one beyond two years
AInvest Wire · Oct 5, 2026Anixa Biosciences - First patient in current cohort shows no cancer progression three months after treatment
AInvest Wire · Oct 5, 2026Anixa Biosciences announces first case of stable disease for three months in ovarian cancer CAR-T clinical trial
AInvest Wire · Oct 5, 2026Anixa Biosciences - No dose-limiting toxicities observed across all cohorts including fifth cohort
Anixa Biosciences Inc. (NASDAQ: ANIX) has reported that no dose-limiting toxicities were observed across all cohorts, including the fifth cohort, in its ongoing clinical trials. This update follows the company’s continued evaluation of its investigational therapies, with safety and tolerability…
AInvest Wire · Oct 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.